Myelodysplastic syndromes (MDS) are clonal disorders of haematopoietic stem cells characterised by ineffective blood cell production, peripheral cytopenias and a risk of progression to acute leukaemia ...
Luspatercept is emerging as a frontline option for lower-risk MDS patients, offering sustained transfusion independence with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results